- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
GUILFORD, Conn. —Mitchell-Vance Labs is in the process of launching a new scar product to add to its ScarAway offering that could appeal to a whole new consumer in search of scar therapy—ScarAway for C-sections.
The therapy may have direct appeal to 1-in-4 new mothers, which is the number of women who give birth by Cesarean section in the United States. According to the March of Dimes, the national weighted average of C-section births is 25.2%, but the percentage of C-sections performed climbs higher than 30% in three states—Mississippi (31.1%), New Jersey (30.9%) and Louisiana (30.4%).
The product features an extended-length, medical-grade silicon scar sheet ideal for placement over C-section cuts.